淋巴管平滑肌瘤病的蛋白质生物标志物及应用

• Format: Patent
• Language: Chinese
• Published: 18.07.2025
• Subjects: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; PHYSICS; TESTING

本发明公开了一种淋巴管平滑肌瘤病的蛋白质生物标志物及应用，属于免疫检测技术领域。具体的包括对受试者血浆中铁蛋白、β2微球蛋白或转铁蛋白任意一种或两种以上组合的表达量进行检测，试验发现血浆中铁蛋白、β2微球蛋白、转铁蛋白含量在淋巴管肌瘤病患者和健康对照组间呈现显著性差异，因此，铁蛋白、β2微球蛋白或转铁蛋白中任意一种或两种以上的组合作为标志物可用于辅助诊断LAM，为协助临床诊疗提供积极意义。 The invention discloses a protein biomarker for lymphangioleiomyomatosis and application thereof, and belongs to the technical field of immunodetection. The method specifically comprises the step of detecting the expression quantity of any one or a combination of more than two of ferritin, beta2 microglobulin or transferrin in the plasma of a subject, and a test finds that the contents of ferritin, beta2 microglobulin and transferrin in the plasma have significant difference between a patient with lymphangioleiomyomatosis and a healthy control group, so that the content of the ferritin, beta2 microglobulin and transferrin in the plasma has significant difference between the patient with lymphangioleiomyomatosis and the healthy control group. Any one or a combination of more than two of ferritin, beta2 microglobulin